A clinical trial with clonazepam (Ro 5-4023).
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001463:Barbiturates / Q000627:therapeutic use; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D002648:Child; D002722:Chlorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010672:Phenytoin; D011324:Primidone / Q000627:therapeutic use; D013997:Time Factors; D014717:Vertigo / Q000139:chemically induced
D000927:Anticonvulsants; D001463:Barbiturates; D001570:Benzodiazepinones; D002722:Chlorobenzenes; D009574:Nitro Compounds; D011324:Primidone; D002220:Carbamazepine; D010672:Phenytoin